Abstract
Dexamethasone-β-D-glucoside is a potential prodrug for colonic delivery of the antiinflammatory agent, dexamethasone. The ability of this prodrug to deliver dexamethasone selectively to the colon depends not only on its being slowly absorbed from the alimentary canal, but also on its having chemical and enzymatic stability in the stomach and small intestine. Once reaching the large bowel, it should be quantitatively hydrolyzed to release the active agent. The potential of dexamethasone-β-D-glucoside for colon-specific delivery of dexamethasone is assessed by determining the rates of its hydrolysis down the alimentary canal of the guinea pig, an animal in which an inflammatory bowel disease model has been developed. The hydrolytic activity is examined in tissues and luminal contents of the stomach, proximal and distal segments of the small intestine, cecum, and colon. For the tissues, the greatest hydrolytic activity is in the proximal small intestine, while the stomach, cecum, and colon have only moderate activity. In contrast, the contents of the cecum and colon show greater activity than the contents of the small intestine and stomach. The luminal contents retained β-glucosidase activity even after repeated centrifugation and resuspension in a buffer. The activity was unaffected by homogenization. These observations suggest that hydrolytic activity is associated with enzymes located on the surface of luminal cells. The movement and hydrolysis of dexamethasone-β-D-glucoside down the gastrointestinal tract of the guinea pig are also examined. About 20 to 30% of an oral dose appears to reach the cecum. Here the prodrug is rapidly hydrolyzed to the active drug. From intravenous administration of the prodrug and drug, it is apparent that dexamethasone-β-D-glucoside is poorly absorbed in the gastrointestinal tract (bioavailability, <1%). There is a ninefold selective advantage for delivery of dexamethasone in cecal tissues in the guinea pig under the conditions of this experiment. Thus, there is a potential for a decrease in the usual dose and a concomitant reduction in the systemic exposure to dexamethasone. Because humans have much less glucosidase activity in the small intestine, even greater site-selective delivery to the cecum and colon is expected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
S. B. Hanauer and J. B. Kirsner. Medical therapy in ulcerative colitis. In J. B. Kirshner and R. G. Shorter (eds.), Inflammatory Bowel Disease, 3rd ed., Lea & Febiger, Philadelphia, 1988, pp. 431–475.
U. Klotz. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokin. 10:285–302 (1985).
G. Jarnerot. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 37:73–86 (1989).
D. A. H. Lee, M. Taylor, V. H. T. Janes, and G. Walker. Rectally administered prednisolone—evidence for a predominantly local action. Gut 21:215–218 (1980).
M. Patterson. Studies on the absorption of hydrocortisone from the colon of patients with idiopathic ulcerative colitis. Tex. Rep. Biol. Med. 16:508–514 (1958).
C. R. Kumana, T. Seaton, M. Meghji, M. Castelli, R. Benson, and S. Thillainathan. Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary adrenal suppression. Lancet 1:579–583 (1982).
G. Hawksworth, B. S. Drasar, and M. J. Hill. Intestinal bacteria and hydrolysis of glycosidic bonds. J. Med. Microbio. 4:451–459 (1971).
D. R. Friend and G. W. Chang. A colon-specific drug delivery system based on drug glycosides and the glycosidases of colonic bacteria. J. Med. Chem. 27:261–267 (1984).
D. R. Friend and G. W. Chang. Drug glycosides: Potential prodrugs for colon-specific drug delivery. J. Med. Chem. 28:51–57 (1985).
P. A. Mackowiak. The normal microbial flora. N. Engl. J. Med. 307:83–93 (1982).
G. L. Simon and S. L. Gorbach. The human intestinal micro-flora. Digest. Dis. Sci. 31 (Suppl. 9):147 S–162 S (1986).
J. Watt and R. Marcus. Carrageenan-induced ulceration of the large intestine in the guinea pig. Gut 12:164–171 (1971).
D. F. Evans, G. Pye, R. Bramley, A. C. Clark, T-J. Dyson, and J. D. Hardcastle. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29:1035–1041 (1988).
U. G. Eriksson and T. N. Tozer. Pharmacokinetic evaluation of regional drug delivery. Acta Pharm. Jugosl. 37:331–344 (1987).
M. Rowland and T. N. Tozer. Clinical Pharmacokinetics, 2nd ed., Lea & Febiger, Philadelphia, 1989.
K. L. Snipes. Anatomy of the guinea pig cecum. Anat. Embryol. 165:97–111 (1982).
G. Pettersson, H. Ahlman, and J. Kewenter. A comparison of small intestinal transit time between the rat and the guinea pig. Acta Chir. Scand. 142:537–540 (1976).
O. P. Malhorta and G. Phillip. Hydrolytic enzymes of mammalian intestines. II. Distribution of hydrolytic enzymes in dog, guinea pig, squirrel, albino rat and rabbit intestines. Ind. J. Med. Red. 53:410–416 (1965).
R. M. Blatt and J. Scott. Response of the small intestinal mucosa to oral glucocorticoids. Scand. J. Gastroenterol. 17 (Suppl. 4):75–88 (1982).
R. M. Blatt and T. J. Peters. Effects of prednisolone on the small intestinal mucosa of the rat. Clin. Sci. Mol. Med. 50:511–523 (1976).
G. Levanti, M. Fehlmann, M. Starita-Geribaldi, and P. Sudaka. Distribution le long de l'intestin du chien des enzymes de la bordure en bosse des enterocytes. Ann. Biol. Anim. Biochem. Biophys. 18:1155–1159 (1978).
J. Conchie and D. C. MacDonald, Glycosidases in the mammalian alimentary canal. Nature London 184:1233 (1959).
J. P. Brown. Hydrolysis of glycosides and esters. In I. R. Rowland (ed.), Role of the Gut Flora in Toxicity and Cancer, Academic Press, London, 1988, pp. 109–144.
B. S. Drasar and M. J. Hill. Human Intestinal Flora, Academic Press, London, 1974, pp. 54–71.
P. Goldman. Biochemical pharmacology and toxicology involving the intestinal flora. In D. J. Hentges (ed.), Human Intestinal Flora in Health and Disease, Academic Press, New York, 1983, pp. 241–263.
A. G. Renwick. First-pass metabolism within the lumen of the gastrointestinal tract. In C. F. George, D. G. Shand, and A. G. Renwick (eds.), Chemical Pharmacology and Therapeutics 1, Presystemic Drug Elimination, Butterworth Scientific, London, 1982, pp. 3–28.
M. Spatz, E. G. McDaniel, and G. L. Laqueur. Cycasin excretion in conventional and germfree rats. Proc. Soc. Biol. Exp. Med. 121:417–422 (1966).
J. D. Hardcastle and J. L. Wilkens. The action of sennosides and related compounds on human colon and rectum. Gut 11:1038–1042 (1970).
S. E. Tsuei, R. G. Moore, J. J. Ashley, and W. G. McBride. Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J. Pharmacokin. Biopharm. 7:249–264 (1979).
G. Tamura, C. Gold, A. Ferro-Luzzi, and B. N. Ames. Fecalase: A model for activation of dietary glycosides to mutagens by intestinal flora. Proc. Natl. Acad. Sci. USA 77:4961–4965 (1980).
D. R. Friend, S. Phillips, A. D. McLeod, and T. N. Tozer. Relative antiinflammatory effect of oral dexamethasone-β-D-glucoside and dexamethasone in experimental inflammatory bowel disease J. Pharm. Pharmacol., in press (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tozer, T.N., Rigod, J., McLeod, A.D. et al. Colon-Specific Delivery of Dexamethasone from a Glucoside Prodrug in the Guinea Pig. Pharm Res 8, 445–454 (1991). https://doi.org/10.1023/A:1015838825437
Issue Date:
DOI: https://doi.org/10.1023/A:1015838825437